AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 1,690,000 shares, a decrease of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily volume of 354,200 shares, the short-interest ratio is presently 4.8 days.

AlloVir Stock Performance

Shares of ALVR stock traded down $0.02 during trading hours on Friday, hitting $0.46. The company had a trading volume of 167,042 shares, compared to its average volume of 589,223. The firm has a market capitalization of $52.81 million, a price-to-earnings ratio of -0.52 and a beta of 0.59. The firm’s fifty day moving average is $0.62 and its 200 day moving average is $0.72. AlloVir has a 12 month low of $0.40 and a 12 month high of $1.05.

AlloVir (NASDAQ:ALVR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC grew its stake in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,816 shares of the company’s stock after acquiring an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.